Targeting Signaling Pathways in Multiple Myeloma

Author(s): Cavallo Federica, Palumbo Antonio, Tricot Guido, Boccadoro Mario.

Journal Name: Current Pharmaceutical Biotechnology

Volume 7 , Issue 6 , 2006

Become EABM
Become Reviewer


Multiple myeloma (MM) is an incurable malignancy of terminally differentiated B-cells accounting for approximately 1 to 2% of all human cancers. The development of MM is believed to be a multistep transformation process that leads to progressive accumulation of genetic alterations. The interaction between MM and bone marrow (BM) microenviroment triggers multiple proliferative and antiapoptotic signaling pathways. Here we discuss the current understanding of signaling pathways, and their potential implication in targeted therapies in MM.

Keywords: Interleukin-6, VEGF, MAPK signaling pathways, Bcl-2 homology, Post Transcriptional Pathways

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2006
Page: [407 - 413]
Pages: 7
DOI: 10.2174/138920106779116883
Price: $65

Article Metrics

PDF: 2